BNET Industries

Market Cap:$14.7M
Last Fiscal Year Sales:$361.0K
  • Public
  • US
Dow Jones Description

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. Our proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly lower doses. Oral sprays eliminate the requirement for water or the need to swallow, potentially improving patient convenience and compliance. Our oral spray technology is focused on addressing unmet medical needs for a broad array of existing and future pharmaceutical products. Our most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. We plan to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. Currently, we have eight patents which have been issued in the U.S. and 69 patents which have been issued outside of the U.S. Additionally, we have over 90 patents pending around the world. We look for drug compounds that are off patent or are coming off patent in the near future, and we formulate these compounds in conjunction with our proprietary drug delivery method. Once formulated, we file for new patent applications on these formulated compounds that comprise our product candidates. ...

Interim President & Chief Executive Officer
Steven B. Ratoff
Number of Employees 14
Contact Information

25 Minneakoning Rd

Flemington

novadel.com

(908) 782-3431

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • NovaDel Releases Financial Results for 3Q and 9 Months Ended September 30

    11/18/09 - Financial Announcement - View Story

  • Hi-Tech Pharmacal to market NovaDel's insomnia spray

    11/17/09 - Joint Venture / Alliance - View Story

  • NovaDel Signs Licensing and Distribution Pact with ECR Pharmaceuticals to Commercialize and Manufacture ZolpiMist

    11/19/09 - Joint Venture / Alliance - View Story

  • PicksThatMove.com Announces Investment Opinion On: Human Genome Science Inc., General Electric...

    11/02/09 - Joint Venture / Alliance - View Story

  • NovaDel Licenses its NitroMist® Lingual Spray to Mist

    10/27/09 - Licensing / Contract - View Story

  • Week of Oct. 19, 2009: Lonza Drops Bid for Patheon; Peregrine Appoints Head of Regulatory...

    10/21/09 - Mgmt. Change Entering - Director - View Story

  • NovaDel Reports Financial Results for Second Quarter and Six

    8/12/09 - Financial Announcement - View Story

News & Analysis

novadel pharma inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Steven B. Ratoff Interim President & Chief Executive Officer
David H. Bergstrom Coo & Senior Vice President
Deni M. Zodda Chief Business Officer & Senior Vice President
Michael E. Spicer Cfo & Secretary
Frank Blondino Executive Director, Formulation & Process Dev
Jay Moorin
Joseph M. Warusz Principal Accounting Officer
Jack J Kornreich Director
Robert F Schaul Director
Robert G. Savage Director
William F. Hamilton Director

Board of Directors

Name (plus bio) Position
Charles Nemeroff Board of Directors
J. Jay Lobell Board of Directors
Mark H. Rachesky Board of Directors
Mark J Baric Board of Directors
Tom Bonney Board of Directors

Organization Position Status
NovaDel Pharma Inc. Interim President & Chief Executive Officer Current
Proquest Investments Venture Partner Current
Axonyx Inc. Chairman Current
NovaDel Pharma Inc. Director and Chairman of The Board, Interim Current
Integrateir Chairman of the Board Current
Doctations Inc. Director Current
NovaDel Pharma Inc. Director Current
Axonyx Inc. Board of Directors Current
Tptx, Inc. Board of Directors Current
Progressive Brands, Inc. Board of Directors Current
CIMA Labs Inc. Interim CEO Former
Macromed, Inc. CEO Former
Macromed, Inc. President Former
Brown-Forman Corporation Chief Financial Officer Former
Bristol-Myers Squibb Company Cfo Former
Brown-Forman Corporation Executive Vice President Former
Bristol-Myers Squibb Company Senior Vice President Former
ProQuest Company Venture Partner Former
Arthur Andersen LLP NA Former
Arthur Anderson & Co. Former
CIMA Labs Inc. Chairman Former
Linux Gold Corp Chairman of the Board Former
University of Michigan M.B.A. Former
Boston University B.S. In Business Administration Former

Organization Position Status
Integrateir Chief Operating Officer & Senior Vice President Current
Linux Gold Corp Chief Operating Officer & Senior Vice President Current
Teryl Resources Corp Chief Operating Officer Current
NovaDel Pharma Inc. Coo & Senior Vice President Current
Guilford Pharmaceuticals, Inc. Vice President of Pharmaceutical and Chemical Development Former
Hoechst Marion Roussel Former
Analytical Sciences Director Former
University of Utah Ph.D. In Pharmaceutics Former
University of Michigan-Ann Arbor M.S. In Pharmaceutical Chemistry Former
University of Michigan M.S. In Pharmaceutical Chemistry Former
Ferris State University B.S. In Pharmacy Former

Organization Position Status
NovaDel Pharma Inc. Chief Business Officer & Senior Vice President Current

Mr. Spicer joins NovaDel as Chief Financial Officer. Mr. Spicer was most recently the Chief Financial Officer of Orchid Biosciences, Inc, a leading provider of identity genetics testing services. At Orchid he played a key role in the successful capital restructuring of the company and its achievement of quarterly operating profitability. Previously, Mr. Spicer served as Vice President, Chief Financial Officer of Lifecodes Corporation from 1998 until it was acquired by Orchid. His background prior to Lifecodes includes over 20 years of finance and accounting experience with White River Corporation, The Chinet Company, Kraft General Foods and Deloitte & Touche. Mr. Spicer is a Certified Public Accountant, and holds an undergraduate degree in Accounting from the University of Virginia and a MBA from Harvard University.

Organization Position Status
Jml Resources Ltd Chief Financial Officer Current
Teryl Resources Corp Chief Financial Officer Current
NovaDel Pharma Inc. Cfo & Secretary Current
Linux Gold Corp Chief Financial Officer & Corporate Secretary Current
Integrateir Chief Financial Officer Current
White River Current
Orchid Biosciences, Inc Chief Financial Officer Former
Orchid Co Former
Harvard University M.B.A Former
University of Virginia Undergraduate Degree In Accounting Former

Organization Position Status
NovaDel Pharma Inc. Executive Director, Formulation & Process Dev Current

Organization Position Status
NovaDel Pharma Inc. Current

Organization Position Status
NovaDel Pharma Inc. Principal Accounting Officer Current

Organization Position Status
Emory University School of Medicine Reunette W. Harris Professor Current
Pfizer Inc. Current
Organon Inc. Current
Wyeth-Ayerst Current
Acadia, Inc Current
Emory University School of Medicine Chairman of the Department of Psychiatry and Behavioral Sciences Current
Linux Gold Corp Director Current
Neurosciencecme Board of Directors Current
Integrateir Director Current
Jml Resources Ltd Director Current
Teryl Resources Corp Director Current
Martin Midstream Partners LP Director Current
NovaDel Pharma Inc. Board of Directors Current
The American College of Psychiatrists President Former
American College of Neuropsychopharmacology President Former
The National Institute of Mental Health Former
ACADIA Pharmaceuticals Inc. Former
National Aeronautics and Space Administration Former
Emory University Professor and Chairman Former
Cypress Bioscience, Inc. Chairman Former
The University of North Carolina at Chapel Hill PhD Former
The University of North Carolina M.D. Former
Northeastern University M.S. Former

Organization Position Status
Paramount Acquisition Corp Chief Executive Officer Current
Paramount Biosciences, LLC Chief Operating Officer Current
Chem Rx Chief Executive Officer, Secretary and Director Current
NovaDel Pharma Inc. Board of Directors Current
Tikvah Therapeutics, Inc. Director Current
Balboa Biosciences Inc. Director Current
Innovive Pharmaceuticals, Inc. Director Current
Integrateir Director Current
Martin Midstream Partners LP Director Current
Teryl Resources Corp Director Current
Linux Gold Corp Director Current
Velcera Pharmaceuticals Inc. President and Secretary Former
Paramount Biosciences, LLC President Current
Eisner LLP Auditor Former
Paramount Acquisition Corp Member of the Board of Directors Former
Yale Law School Jd Former
Erasmus University M.D. Former
Stanford University Mba Degree Former
Queens College BA Former
Harvard Medical School Former

Organization Position Status
NovaDel Pharma Inc. Director Current

Organization Position Status
NationsHealth, Inc. Co-Founder Current
East Coast Diabetic Supply Co-Founder Current
Neose Technologies, Inc. Board of Directors Current
Loral Space & Communications, Inc. Chairman Current
Telesat Canada Non-Executive Chairman of the Board Current
Leap Wireless International, Inc. Member and Chairman Current
NationsHealth, Inc. Board of Directors Current
Keryx Biopharmaceuticals, Inc. Director Current
NovaDel Pharma Inc. Board of Directors Current
Lions Gate Entertainment Corp. Board of Directors Current
Emisphere Technologies, Inc. Board of Directors Current
East Coast Diabetic Supply Board of Directors Current
Leap Wireless International, Inc. Board of Directors Former
Stanford University School of Medicine M.D. Former
Stanford University M.B.A. Former
University of Pennsylvania BS Former

Array

Organization Position Status
Cenerx Biopharma, Inc. Co-Founder Current
Cenerx Biopharma, Inc. Board of Directors Current
Martin Midstream Partners LP Director Current
NovaDel Pharma Inc. Board of Directors Current
Integrateir Director Current
Linux Gold Corp Board of Directors Current
Concert Technologies Board of Directors Current
Seer Technologies Chief Financial and Administrative Officer Former
Clarion University M.B.A. Former
Wharton Graduate School of the University of Pennsylvania M.B.A. Former
Clarion University B.S. Former

Organization Position Status
NovaDel Pharma Inc. Director Current

Organization Position Status
Vela Pharmaceuticals, Inc. Current
EpiCept Corporation Non-Executive Chairman of the Board Current
Noven Pharmaceuticals, Inc. Chairperson Current
JDS Pharmaceuticals, LLC Chairperson Current
The Medicines Company Director Current
Angiox Board of Directors Current
Noven Pharmaceuticals, Inc. Director Current
NovaDel Pharma Inc. Director Current
Johnson & Johnson President Former
The Group Inc. President Former
Pharmacia Corporation President Former
Johnson & Johnson Vice President Sales & Marketing Former
The Medicines Company Vice President Former
Pharmacia Corporation Group Vice President Former
Johnson & Johnson Chairman Former
The Group Inc. Chairman Former
The Medicines Company Chair Former
EpiCept Corporation Board of Directors Former
Rutgers University MBA Former
Upsala College B.S. In Biology Former

With over 20 years of experience in financial, operations, technology and business development areas, Tom brings an informed, broad, and deep level of expertise to our client's strategic and tactical issues across many industry groups (manufacturing, retail, professional services, technology, and pharmaceuticals). He is a recognized expert on middle market operations, integration of acquisitions, European/US business relationships, and business strategies. Prior to CMF Associates, Tom led a profitable high technology consultancy practice, Polaris Consulting & Information Technologies, and worked at Deloitte & Touche in their accounting and audit practices in Philadelphia and London. Tom also serves as the Audit Committee Chairman at NovaDel Pharmaceuticals (AMEX:NVD). In addition, he serves as an adjunct professor at Temple University where he teaches business strategy and continues to foster entrepreneurship at local universities as a judge for business plan competitions at Temple University and Drexel University. He speaks frequently on various business topics and has had several articles published on practical applications of information technology in local magazines. Tom is a member of the Pennsylvania Institute of Certified Public Accountants and graduated Magna Cum Laude and was a University Scholar at Penn State University.

Organization Position Status
Cmf Associates, LLC President Current
Cmf Associates, LLC Founder and Managing Director Current
Temple University Adjunct Professor Current
Pennsylvania Institute of Certified Public Accountants Board of Directors Current
Linux Gold Corp Director Current
Teryl Resources Corp Director Current
Jml Resources Ltd Director Current
Integrateir Director Current
Martin Midstream Partners LP Director Current
NovaDel Pharma Inc. Board of Directors Current
Polaris Consulting Partner Former
Information Technologies, Inc. Partner Former
MRI Former
CDI Corp. Former
Deloitte & Touche LLP Former
The Pennsylvania State University B.S. In Accounting Former

Organization Position Status
Yaupon Therapeutics Landau Professor of Management and Technology Current
Mentortech Ventures Chairman Current
Martin Midstream Partners LP Director Current
Linux Gold Corp Director Current
Teryl Resources Corp Director Current
Integrateir Director Current
Neuronyx Director Current
NovaDel Pharma Inc. Director Current
Jml Resources Ltd Director Current
Yaupon Therapeutics Director Current
Neuro Diagnostic Devices Board of Directors Current
University of Pennsylvania Faculty Former
The Wharton School of the University of Pennsylvania Director Former
Neose Technologies, Inc. Director Current
The London School of Economics Ph.D. In Applied Economics Former
The London School of Economics M.S. In Chemical Engineering Former
University of Pennsylvania M.B.A. Former
The London School of Economics B.S. Former

Executive News

  • TV boosts Lions Gate quarterly earnings

    FOX 43 - 8/11/09 - View Story

  • Television delivers strong quarter for Lions Gate

    Los Angeles Times - 8/10/09 - View Story

  • NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months

    Reuters - 7/20/09 - View Story

  • NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months

    Business Wire - 7/20/09 - View Story

  • Conflict With My Interests

    Inside Higher Ed - 7/10/09 - View Story

  • Double Standard at Emory?

    Inside Higher Ed - 7/01/09 - View Story

  • NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the...

    Forbes.com - 6/29/09 - View Story

  • NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the Next 12 Months

    Reuters - 6/29/09 - View Story

  • NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the Next 12 Months

    Business Wire - 6/29/09 - View Story

advertisement
     NVD $0.23 0.00 (0.00% )
Average Volume 456,336
Shares Outstanding 64.11M
Market Cap 14.7M
Year High 0.88
Year Low 0.0504
Earnings Per Share -0.12
P/E Ratio -1.92
Dividend N/A
Yield N/A
advertisement